Bibliographies thématiques / Tumefactive demyelinating lesions

Sommaire

Articles de revues
Thèses
Chapitres de livres
Actes de conférences

Littérature scientifique sur le sujet « Tumefactive demyelinating lesions »

Auteur : Grafiati

Publié le 7 juin 2025

Mis à jour le 2 août 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Tumefactive demyelinating lesions ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Tumefactive demyelinating lesions"

Barbosa, Brainner Campos, Edson Marchiori, Caio Leal Leidersnaider, Lara Brandao, and Mauricio Castillo. "Demyelinating lesions behaving like aggressive tumours on advanced MRI techniques." Neuroradiology Journal 32, no. 2 (2019): 103–7. http://dx.doi.org/10.1177/1971400919826394.

Texte intégral

Résumé :

Tumefactive demyelinating lesions are a rare disorder in which inflammatory demyelination manifests as solitary or multiple focal brain lesions (greater than 2 cm in size), which can be mistaken for glioma, lymphoma, metastasis and in some cases even brain abscess. The symptomatology of tumefactive demyelinating lesions depends on the white matter area involved and includes quickly progressing neurological deterioration of motor, sensory and visual function, praxis, language and mood impairment, as well as seizures. Recognising the key imaging features in a patient with a prior history of demy

Styles APA, Harvard, Vancouver, ISO, etc.

Brod, Staley A., J. William Lindsey, and Flavia Nelson. "Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments." Multiple Sclerosis Journal - Experimental, Translational and Clinical 5, no. 2 (2019): 205521731985575. http://dx.doi.org/10.1177/2055217319855755.

Texte intégral

Résumé :

Objective Large demyelinating lesions with possible mass effect (tumefactive multiple sclerosis or tumefactive demyelination) can be mistaken for tumour-like space-occupying lesions suggesting a malignant outcome. Methods We reviewed our own experience of multiple sclerosis subjects ( n = 28) with tumefactive demyelination to determine the relationship between clinical outcomes and lesion evolution, clinical outcomes and their relationship to different therapies. Patients with central nervous system demyelinating disease were identified from our database over the last 10 years. Results No pati

Styles APA, Harvard, Vancouver, ISO, etc.

Weinshenker, Brian G. "Tumefactive demyelinating lesions: Characteristics of individual lesions, individual patients, or a unique disease entity?" Multiple Sclerosis Journal 21, no. 13 (2015): 1746–47. http://dx.doi.org/10.1177/1352458515603801.

Texte intégral

Résumé :

Whether or not recurrent tumefactive demyelinating lesions are a unique form of CNS demyelinating disease or part of the continuum of multiple sclerosis is a question raised by the case report on which this commentary is based. Detailed review and immunopathologic study of biopsy material may not only confirm or refute a diagnosis of demyelinating disease, but potentially uncover unique features that may assist in understanding pathophysiology and nosology of rare cases with recurrent tumefactive demyelination.

Styles APA, Harvard, Vancouver, ISO, etc.

Hudon, Mark, Richard Farb, A. P. Mitha, et al. "Tumefactive Demyelinating Lesions." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 34, no. 3 (2007): 362–64. http://dx.doi.org/10.1017/s0317167100006831.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Dagher, A. P., and J. Smirniotopoulos. "Tumefactive demyelinating lesions." Neuroradiology 38, no. 6 (1996): 560–65. http://dx.doi.org/10.1007/s002340050308.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Dagher, A. P., and J. Smirniotopoulos. "Tumefactive demyelinating lesions." Neuroradiology 38, no. 6 (1996): 560–65. http://dx.doi.org/10.1007/bf00626098.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Zafar, Lubna, Obaid Ahmed Siddiqui, Shazia Durdana, and Damera Achyuth Kumar. "Tumefactive demyelination-A Rare Presentation of Multiple Sclerosis." Bangladesh Journal of Medical Science 21, no. 4 (2022): 931–34. http://dx.doi.org/10.3329/bjms.v21i4.60259.

Texte intégral

Résumé :

Background: Multiple Sclerosis is an inflammatory demyelinating disease having varied manifestations in terms of clinical featuresand radiological features. Rarely it may present as a large demyelinating lesionwith accompanying edema and mass effect, thereby simulating an intracranial tumor, known as Tumefactive Demyelination. Symptoms are usually related to the pressure of a focal mass lesion. When it manifests in a patient without pre-existing MS, it poses a diagnostic challengeas it may mimic a neoplasm, infarct or abscess. Thus, it is essential to recognize this rare clinical entity for pr

Styles APA, Harvard, Vancouver, ISO, etc.

Kalanie, Hossein, Ali Amini Harandi, Reza Bakhshandehpour, and Daryoosh Heidari. "Multiple Large Tumefactive MS Plaques in a Young Man: A Diagnostic Enigma and Therapeutic Challenge." Case Reports in Radiology 2012 (2012): 1–5. http://dx.doi.org/10.1155/2012/363705.

Texte intégral

Résumé :

Tumefactive demyelinating lesion is defined as large solitary demyelinating lesion with imaging characteristics mimicking neoplasm. These atypical features include size more than 2 cm, mass effect, edema, and/or ring enhancement. Distinguishing tumefactive lesions from other etiologies of intracranial space occupying lesions is essential to avoid inadvertent surgical or toxic chemotherapeutic intervention. Symptoms are generally atypical for multiple sclerosis (MS) and usually related to the pressure of a focal mass lesion without a history of MS. The clinical presentation and MRI appearance o

Styles APA, Harvard, Vancouver, ISO, etc.

QI, WEI, GE JIA, XINSHENG WANG, MAOZHI ZHANG, and ZHENYU MA. "Cerebral tumefactive demyelinating lesions." Oncology Letters 10, no. 3 (2015): 1763–68. http://dx.doi.org/10.3892/ol.2015.3481.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Altintas, A., B. Petek, N. Isik, et al. "Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study." Multiple Sclerosis Journal 18, no. 10 (2012): 1448–53. http://dx.doi.org/10.1177/1352458512438237.

Texte intégral

Résumé :

Background: Demyelinating lesions over 20 mm in size, referred to as tumefactive demyelinating lesions, can be misdiagnosed as being either a tumor or an abscess. Although some radiological characteristics can help make a differential diagnosis easier, a cerebral biopsy may still be necessary. Objective: Our objective was to assess the clinical characteristics of tumefactive lesions, with or without a diagnosis of multiple sclerosis (MS), and present follow-up data for 54 patients with tumefactive lesions. Methods: Demographic, clinical, radiological and laboratory data were gathered and treat

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Thèses sur le sujet "Tumefactive demyelinating lesions"

Santos, Stella de Aparecida Ederli Pinto dos. "Diagnóstico diferencial das lesões tumefativas desmielizantes do sistema nervoso central na infância e adolescência: revisão sistemática da literatura." Instituto Fernandes Figueira, 2013. https://www.arca.fiocruz.br/handle/icict/10988.

Texte intégral

Résumé :

Made available in DSpace on 2015-06-26T13:08:44Z (GMT). No. of bitstreams: 2 stella_aparecida_iff_mest_2013.pdf: 2260165 bytes, checksum: eb12d331363220960351de6e8f16c16d (MD5) license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5) Previous issue date: 2013<br>Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Departamento de Ensino. Programa de Pós-Graduação em Saúde da Criança e da Mulher. Rio de Janeiro, RJ, Brasil.<br>As lesões tumefativas desmielinizantes (LTD) do SNC apresentam extrema dificuldade diagnóstica

Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "Tumefactive demyelinating lesions"

"Tumefactive Demyelinating Lesions (TDL)." In Neuropathology. Elsevier, 2014. http://dx.doi.org/10.1016/b978-1-4160-6220-2.00050-6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Kalinowska-Lyszczarz, Alicja, W. Oliver Tobin, Yong Guo, and Claudia F. Lucchinetti. "Fluctuating Vision Loss, Seizures, and Left Parieto-Occipital Mass." In Mayo Clinic Cases in Neuroimmunology, edited by Andrew McKeon, B. Mark Keegan, and W. Oliver Tobin. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780197583425.003.0007.

Texte intégral

Résumé :

A 35-year-old man sought care for progressive visual disturbance. Magnetic resonance imaging of the brain showed a large, left-sided, parieto-occipital, contrast-enhancing lesion. He was treated with dexamethasone with brief improvement in vision. Within 5 days he had progressive vision worsening. Two weeks after the onset of his symptoms, brain magnetic resonance imaging showed a decrease in lesion size, and corticosteroids were discontinued. Two months after symptom onset he was found to have alexia without agraphia, and follow-up magnetic resonance imaging showed an increased size of the le

Styles APA, Harvard, Vancouver, ISO, etc.

Litsou, Eleni. "Atypical Presentation or Variants of Multiple Sclerosis." In Multiple Sclerosis - Pathways, Diagnosis and Therapeutic Targets [Working Title]. IntechOpen, 2025. https://doi.org/10.5772/intechopen.1010042.

Texte intégral

Résumé :

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder (DD) of the central nervous system (CNS), characterized by the presence of multifocal lesions, axonal degeneration, and reactive gliosis. Remyelination may occur, particularly in the early phases of lesion development, although its extent varies among individuals. Pathological studies have highlighted significant inter-individual differences in oligodendrocyte preservation and distinct mechanisms of demyelination, including T-cell/macrophage-mediated processes, antibody/complement-mediated injury, and primary oligodendroc

Styles APA, Harvard, Vancouver, ISO, etc.

McKeon, Andrew. "A Woman With Headaches and a Tumefactive Brain Lesion." In Mayo Clinic Cases in Neuroimmunology, edited by Andrew McKeon, B. Mark Keegan, and W. Oliver Tobin. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780197583425.003.0065.

Texte intégral

Résumé :

A 65-year-old woman sought care for a 6-month history of confusion and emotional disturbance that was initially ascribed to stress. She then had development of headaches over several weeks, which prompted brain magnetic resonance imaging with contrast. Imaging showed a mass emanating bilaterally from the splenium of the corpus callosum with heterogeneous T1 postgadolinium enhancement. Neurologic examination indicated left homonymous hemianopia, but she was otherwise normal. She had neither alexia nor other language deficit that may appear with a splenial corpus callosum lesion. A biopsy of the

Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Tumefactive demyelinating lesions"

Silva, Agnes Laura, Beatriz Iolanda de Sene Ferregutti Pinheiro, Laura de Lourdes Cardoso e. Silva, et al. "Pseudotumor demyelination lesion associated with bevacizumab in oncological treatment." In XIV Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2023. http://dx.doi.org/10.5327/1516-3180.141s1.770.

Texte intégral

Résumé :

Introduction: Bevacizumab is a monoclonal antibody directed against the human isoform of vascular endothelial growth factor A (VEGF-A) and inhibits angiogenesis. Case: Female patient, 54-year-old, with a history of intestinal adenocarcinoma associated with peritoneal carcinomatosis being treated with bevacizumab. The patient started to present a deviation of the labial rhyme to the right, which showed the presence of left facial paralysis with a central pattern on the neurological physical examination, without other alterations. Magnetic resonance imaging of the brain showed a nodular lesion c

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!